Lilly And Investors Spin Out Xigris To Form New Critical Care Company BioCritica
This article was originally published in The Pink Sheet Daily
Executive Summary
Initial focus of the private biotech will be on continued development and commercialization of Xigris for sepsis; investment backers are NovaQuest Capital and Care Capital.